Alkermes is a global biopharmaceutical company focused on developing and commercializing innovative medicines in neuroscience, with a portfolio of proprietary extended-release and controlled-release medications for schizophrenia, bipolar disorder, opioid and alcohol dependence, and narcolepsy. The company generates revenue through three main channels: direct sales of branded products including ARISTADA, LYBALVI, VIVITROL, and LUMRYZ through its own U.S. sales force; tiered royalty payments from pharmaceutical partners like Janssen and Biogen who license its proprietary delivery technologies (NANOCRYSTAL, LINKERX, and microsphere platforms); and contract manufacturing of pharmaceutical products. Alkermes serves large neurological markets with significant unmet medical needs, reaching physicians, treatment providers, and patients through pharmaceutical wholesalers and specialty distributors, while maintaining research and development capabilities alongside manufacturing operations.